Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Chelating agents for the treatment of systemic iron overload.

Ma Y, Zhou T, Kong X, Hider RC.

Curr Med Chem. 2012;19(17):2816-27. Review.

PMID:
22455586
2.

Design of iron chelators with therapeutic application.

Zhou T, Ma Y, Kong X, Hider RC.

Dalton Trans. 2012 Jun 7;41(21):6371-89. doi: 10.1039/c2dt12159j. Epub 2012 Mar 6. Review.

PMID:
22391807
4.
5.

New developments in iron chelators.

Cunningham MJ, Nathan DG.

Curr Opin Hematol. 2005 Mar;12(2):129-34. Review.

PMID:
15725903
6.

Design of clinically useful iron(III)-selective chelators.

Liu ZD, Hider RC.

Med Res Rev. 2002 Jan;22(1):26-64. Review.

PMID:
11746175
7.

Coordination chemistry and biology of chelators for the treatment of iron overload disorders.

Bernhardt PV.

Dalton Trans. 2007 Aug 14;(30):3214-20. Epub 2007 Jul 5. Review.

PMID:
17893764
8.

Orally active iron chelators in the treatment of iron overload.

Olivieri NF.

Curr Opin Hematol. 1996 Mar;3(2):125-30. Review.

PMID:
9372062
9.

The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.

Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A.

Curr Med Chem. 2004 Aug;11(16):2161-83. Review.

PMID:
15279556
10.

Iron chelator research: past, present, and future.

Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M.

Curr Med Chem. 2003 Jun;10(12):983-95. Review.

PMID:
12678671
11.

Thalassemia.

Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E.

Hematology Am Soc Hematol Educ Program. 2004:14-34. Review.

PMID:
15561674
12.

Synthetic and natural iron chelators: therapeutic potential and clinical use.

Hatcher HC, Singh RN, Torti FM, Torti SV.

Future Med Chem. 2009 Dec;1(9):1643-70. doi: 10.4155/fmc.09.121. Review.

13.

Development of tridentate iron chelators: from desferrithiocin to ICL670.

Nick H, Acklin P, Lattmann R, Buehlmayer P, Hauffe S, Schupp J, Alberti D.

Curr Med Chem. 2003 Jun;10(12):1065-76. Review.

PMID:
12678677
14.

Treatment of iron overload in thalassemia.

Cianciulli P.

Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:208-13. Review.

PMID:
19337180
15.
16.

Beta-thalassaemia: emergence of new and improved iron chelators for treatment.

Wong C, Richardson DR.

Int J Biochem Cell Biol. 2003 Jul;35(7):1144-9. Review.

PMID:
12672484
17.

Iron chelators as therapeutic agents for the treatment of cancer.

Richardson DR.

Crit Rev Oncol Hematol. 2002 Jun;42(3):267-81. Review.

PMID:
12050019
18.

Design of clinically useful macromolecular iron chelators.

Zhou T, Winkelmann G, Dai ZY, Hider RC.

J Pharm Pharmacol. 2011 Jul;63(7):893-903. doi: 10.1111/j.2042-7158.2011.01291.x. Epub 2011 May 19. Review.

PMID:
21635254
19.

PCTH: a novel orally active chelator for the treatment of iron overload disease.

Lovejoy DB, Kalinowski D, Bernhardt PV, Richardson DR.

Hemoglobin. 2006;30(1):93-104. Review.

PMID:
16540421
20.

Secondary iron overload.

Kushner JP, Porter JP, Olivieri NF.

Hematology Am Soc Hematol Educ Program. 2001:47-61. Review.

PMID:
11722978
Items per page

Supplemental Content

Write to the Help Desk